Trial Profile
A Phase III, Randomized, Double-Blind, Multi-center Study to Investigate the Efficacy and Safety of Camrelizumab+Gemcitabine+Cisplatin Versus Placebo+Gemcitabine+Cisplatin in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CAPTAIN-1st
- Sponsors Jiangsu Hengrui Medicine Co.
- 30 Jun 2022 Planned End Date changed from 1 Nov 2021 to 31 Dec 2022.
- 01 May 2022 Results evaluating the cost-effectiveness of toripalimab or camrelizumab combined with gemcitabine plus cisplatin2 and GP alone by deriving survival data from the CAPTAIN-1st and JUPITER-02 trials, published in the Oral Oncology
- 23 Jun 2021 Results comparing camrelizumab plus gemcitabine and cisplatin with placebo plus gemcitabine and cisplatin published in the Lancet Oncology